Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease
The specific and significant COVID-19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics s …